<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01883804</url>
  </required_header>
  <id_info>
    <org_study_id>13-1408</org_study_id>
    <nct_id>NCT01883804</nct_id>
  </id_info>
  <brief_title>Effect of Methyldopa on MHC Class II Antigen Presentation in Type 1 Diabetes</brief_title>
  <official_title>Open Label Pilot Study of the Effect of Methyldopa on MHC-II Antigen Presentation in Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado Denver School of Medicine Barbara Davis Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado Denver School of Medicine Barbara Davis Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 1 Diabetes is an autoimmune condition in which segments of the immune system cause the
      destruction of insulin producing cells in the pancreas, leaving individuals with an impaired
      ability to control blood glucose levels. Currently there is no cure for Type 1 Diabetes and
      the treatments involve lifelong insulin administration and careful monitoring of blood
      glucose levels. Long-term complications like cardiovascular disease, nerve damage, and retina
      damage, may result. Previous studies have shown that improvement in the control of blood
      glucose can reduce the risks from these long-term complications. Residual insulin production,
      typically within the first few years following diagnosis, helps to reduce an individual's
      need to supplement insulin by injection or pump. This effect helps in maintaining the body's
      ability to regulate blood glucose levels and reducing the needs of external insulin.

      Methyldopa, or Aldomet, has been approved by the Food and Drug Administration and is commonly
      used to treat high blood pressure. This drug has been approved for several decades and has
      been shown to be safe and effective. This drug has been identified by the researcher to be
      able to block the communication between two important types of immune cells; which play a
      critical role in the autoimmune processes of Type 1 Diabetes. The investigators hypothesize
      that Methyldopa, over a 6 week treatment period, will block this communication and possibly
      slow down the destruction of insulin producing cells. The investigators hope to assess the
      appropriate and safe dose to achieve this effect, along with the drug's ability to maintain
      insulin production and blood glucose control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Change From Baseline of DQ8 Antigen Presentation by Peripheral Blood Mononuclear Cells After 6 Weeks of Methyldopa Treatment.</measure>
    <time_frame>6 Weeks (Baseline and week 6)</time_frame>
    <description>Cryopreserved primary peripheral blood mononuclear cells were used as antigen presenting cells to stimulate engineered T-cells (T-cell receptor transductant) responding to a specific peptide presented by HLA-DQ8. Secreted IL-2 from the engineered T-cell was measured by a highly sensitive ELISA. This was done for both an Î±-gliadin/DQ8 responding T-cell and a separate insulin/DQ8 responding T-cell.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Change in C-Peptide AUC Following a MMTT From Baseline to Study Completion.</measure>
    <time_frame>12 weeks (Baseline and week 12)</time_frame>
    <description>Investigators aim to observe changes in residual endogenous insulin production as measured by C-peptide 2 hour area under the curve following a Mixed Meal Tolerance Test (MMTT). C-peptide is a measure of endogenous insulin secretion as both are secreted in a 1:1 molar ratio. Individuals ingested a liquid meal (Boost) with a fixed amount of protein, fat and carbohydrate in the fasting state followed by the timed measurements of serum C-peptide at 0, 15, 30, 60, 90 and 120 minutes to compute the AUC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change in Hemoglobin A1c From Baseline to Study Completion.</measure>
    <time_frame>12 weeks (Baseline and week 12)</time_frame>
    <description>Investigators aim to observe changes in hemoglobin A1c values, a measure of average blood glucose over the preceding 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change in Insulin Use From Baseline to Study Completion.</measure>
    <time_frame>12 weeks (Baseline and week 12)</time_frame>
    <description>Exogenous insulin use per kg of body weight.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants selected to continue with Methyldopa administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methyldopa</intervention_name>
    <description>6 weeks of Methyldopa administration; where the dose will be increased according to safety of efficacy.</description>
    <arm_group_label>Study group</arm_group_label>
    <other_name>Aldomet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Type 1 Diabetes Mellitus

          -  18-46 years of age

          -  Residual C-peptide production during screening

          -  Positive for at least one islet autoantibody: insulin (if only insulin autoantibody
             positive, determination must be within two weeks of insulin initiation), GAD-65, IA-2
             or ZnT8

          -  Positive for at least one gene encoding HLA-DQ8 (DQB*0302)

          -  No history of difficult to control hypertension (defined as requiring &gt; 2
             anti-hypertensive medications)

          -  Agree to intensive management of diabetes with an HgbA1c goal of &lt; 8.0%

          -  If female: (a) surgically sterile or (b) postmenopausal or (c) if of reproductive
             potential, willing to use medically acceptable birth control (e.g. female hormonal
             contraception, barrier methods or sterilization.) until study completion

          -  If male and of reproductive potential, willing to use medically acceptable birth
             control until study completion, unless the female partner is postmenopausal or
             surgically sterile

        Exclusion Criteria:

          -  Unable or unwilling to comply with the requirements of the study protocol

          -  No HLA-DQ8 gene (DQB*0302)

          -  Difficult to control hypertension (defined as requiring &gt; 2 anti-hypertensive
             medications)

          -  History of postural hypotension or Addison's disease

          -  Body Mass Index (BMI) &gt; 30 kg/m2

          -  Unstable blood sugar control defined as one or more episodes of severe hypoglycemia
             (defined as hypoglycemia that required the assistance of another person) within the
             last 30 days

          -  Administration of an experimental agent for T1D at any time or use of an experimental
             device for T1D within 30 days of screening, unless approved by the study PI

          -  History of any organ transplant, including islet cell transplant

          -  Active autoimmune or immune deficiency disorder (e.g. sarcoidosis, rheumatoid
             arthritis)

          -  Anticipated pregnancy during the 12 week study period

          -  Any social or medical condition that would, in the opinion of the investigator,
             prevent complete participation in the study or that would pose a significant hazard to
             the subjects' participation

          -  History of active substance abuse within 12 months of screening

          -  A psychiatric or medical disorder that would prevent giving informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>46 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aaron Michels, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barbara Davis Center for Diabetes, University of Colorado School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Davis Center for Diabetes, University of Colorado School of Medicine</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.barbaradaviscenter.org/</url>
    <description>Barbara Davis Center Website</description>
  </link>
  <results_reference>
    <citation>Ostrov DA, Alkanani A, McDaniel KA, Case S, Baschal EE, Pyle L, Ellis S, PÃ¶llinger B, Seidl KJ, Shah VN, Garg SK, Atkinson MA, Gottlieb PA, Michels AW. Methyldopa blocks MHC class II binding to disease-specific antigens in autoimmune diabetes. J Clin Invest. 2018 May 1;128(5):1888-1902. doi: 10.1172/JCI97739. Epub 2018 Apr 3.</citation>
    <PMID>29438107</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2013</study_first_submitted>
  <study_first_submitted_qc>June 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2013</study_first_posted>
  <results_first_submitted>March 1, 2018</results_first_submitted>
  <results_first_submitted_qc>March 1, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 29, 2018</results_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Colorado Denver School of Medicine Barbara Davis Center</investigator_affiliation>
    <investigator_full_name>Aaron Michels, MD</investigator_full_name>
    <investigator_title>Effect of Methyldopa on MHC class II Antigen Presentation in Type 1 Diabetes</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Type 1 Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methyldopa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited through the adult clinic of the Barbara Davis Center, University of Colorado School of Medicine. Recruitment began in July of 2013 and concluded in November of 2015.</recruitment_details>
      <pre_assignment_details>A total of 30 participants joined the study. Five participants withdrew prior to the first visit or any study procedures. The remaining 25 participants started the study and 20 completed all study visits and procedures.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Methyldopa Group</title>
          <description>All participants selected to continue with Methyldopa administration.
Methyldopa: 6 weeks of Methyldopa administration; where the dose will be increased according to safety of efficacy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis population includes those participants that completed the course of the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Study Group</title>
          <description>All participants selected to continue with Methyldopa administration.
Methyldopa: 6 weeks of Methyldopa administration; where the dose will be increased according to safety of efficacy.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Mean Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.75" lower_limit="18" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Type 1 Diabetes</title>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133" lower_limit="21" upper_limit="566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1c</title>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.4" lower_limit="5.3" upper_limit="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>C-Peptide AUC following a 2 Hour Mixed Meal Tolerance Test</title>
          <units>nmol/L/Min</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.64" lower_limit="0.10" upper_limit="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Positive Insulin Autoantibodies (Index)</title>
          <description>Only included if measured within 21 days of starting exogenous insulin.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Positive GAD Autoantibodies</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Positive IA-2 Autoantibodies</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Positive ZnT8 Autoantibodies</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113.2" spread="10.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.65" spread="8.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Elevated AST Values</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Elevated ALT Values</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Abnormal Hemoglobin Levels</title>
          <description>Hemoglobin &lt; 12 g/dL</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Change From Baseline of DQ8 Antigen Presentation by Peripheral Blood Mononuclear Cells After 6 Weeks of Methyldopa Treatment.</title>
        <description>Cryopreserved primary peripheral blood mononuclear cells were used as antigen presenting cells to stimulate engineered T-cells (T-cell receptor transductant) responding to a specific peptide presented by HLA-DQ8. Secreted IL-2 from the engineered T-cell was measured by a highly sensitive ELISA. This was done for both an Î±-gliadin/DQ8 responding T-cell and a separate insulin/DQ8 responding T-cell.</description>
        <time_frame>6 Weeks (Baseline and week 6)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Group</title>
            <description>open label treatment; dose escalation of methyldopa</description>
          </group>
        </group_list>
        <measure>
          <title>The Change From Baseline of DQ8 Antigen Presentation by Peripheral Blood Mononuclear Cells After 6 Weeks of Methyldopa Treatment.</title>
          <description>Cryopreserved primary peripheral blood mononuclear cells were used as antigen presenting cells to stimulate engineered T-cells (T-cell receptor transductant) responding to a specific peptide presented by HLA-DQ8. Secreted IL-2 from the engineered T-cell was measured by a highly sensitive ELISA. This was done for both an Î±-gliadin/DQ8 responding T-cell and a separate insulin/DQ8 responding T-cell.</description>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, Î±-gliadin/DQ8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="642" spread="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 weeks of treatment, Î±-gliadin/DQ8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="430" spread="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, insulin/DQ8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 weeks of treatment, insulin/DQ8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change in C-Peptide AUC Following a MMTT From Baseline to Study Completion.</title>
        <description>Investigators aim to observe changes in residual endogenous insulin production as measured by C-peptide 2 hour area under the curve following a Mixed Meal Tolerance Test (MMTT). C-peptide is a measure of endogenous insulin secretion as both are secreted in a 1:1 molar ratio. Individuals ingested a liquid meal (Boost) with a fixed amount of protein, fat and carbohydrate in the fasting state followed by the timed measurements of serum C-peptide at 0, 15, 30, 60, 90 and 120 minutes to compute the AUC.</description>
        <time_frame>12 weeks (Baseline and week 12)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Group</title>
            <description>open label treatment; dose escalation of methyldopa</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in C-Peptide AUC Following a MMTT From Baseline to Study Completion.</title>
          <description>Investigators aim to observe changes in residual endogenous insulin production as measured by C-peptide 2 hour area under the curve following a Mixed Meal Tolerance Test (MMTT). C-peptide is a measure of endogenous insulin secretion as both are secreted in a 1:1 molar ratio. Individuals ingested a liquid meal (Boost) with a fixed amount of protein, fat and carbohydrate in the fasting state followed by the timed measurements of serum C-peptide at 0, 15, 30, 60, 90 and 120 minutes to compute the AUC.</description>
          <units>nmol/L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Completion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change in Hemoglobin A1c From Baseline to Study Completion.</title>
        <description>Investigators aim to observe changes in hemoglobin A1c values, a measure of average blood glucose over the preceding 3 months.</description>
        <time_frame>12 weeks (Baseline and week 12)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Group</title>
            <description>open label treatment; dose escalation of methyldopa</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Hemoglobin A1c From Baseline to Study Completion.</title>
          <description>Investigators aim to observe changes in hemoglobin A1c values, a measure of average blood glucose over the preceding 3 months.</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Completion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change in Insulin Use From Baseline to Study Completion.</title>
        <description>Exogenous insulin use per kg of body weight.</description>
        <time_frame>12 weeks (Baseline and week 12)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Group</title>
            <description>open label treatment; dose escalation of methyldopa</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Insulin Use From Baseline to Study Completion.</title>
          <description>Exogenous insulin use per kg of body weight.</description>
          <units>units/Kg body weight</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Completion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Over the course of the 12 week study.</time_frame>
      <desc>Adverse event collection occurred at each visit through standard questions asked by the research coordinator and discussions with the investigator.</desc>
      <group_list>
        <group group_id="E1">
          <title>Study Group</title>
          <description>All participants selected to continue with Methyldopa administration.
Methyldopa: 6 weeks of Methyldopa administration; where the dose will be increased according to safety of efficacy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>A state of generalized weakness with a pronounced inability to summon sufficient energy to accomplish daily activities. Grade 2 are reported.</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Aaron Michels</name_or_title>
      <organization>Barbara Davis Center for Diabetes, University of Colorado School of Medicine</organization>
      <phone>303-724-1923</phone>
      <email>aaron.michels@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

